Development of Iron Complexes for the Treatment of FriedreichÍs Ataxia & the Role of Frataxin in Iron Metabolism

开发用于治疗弗里德赖希共济失调的铁络合物

• 批准号: nhmrc : 1002867
• 负责人: Dr Yohan Suryo Rahmanto
• 金额: $ 41.08万
• 依托单位: The University of Sydney
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2011
• 资助国家: 澳大利亚
• 起止时间: 2011-01-01 至 2014-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/development-iron-complexes-iron-metabolism/108866
• 关键词: Development; Iron; Complexes; Treatment; Friedreich

Friedreich's ataxia (FA) is a neuro- & cardio-degenerative disease where there is an accumulation of toxic iron (Fe) in the mitochondrion. Work from our current NHMRC grant showed iron plays a significant role in FA pathology In fact, the CIs dissected the mechanisms of mitochondrial iron-loading & have published 8 papers in high impact journals with 3 papers in PNAS USA in the last 2 yrs Understanding of this process has led to the design of rationalised drugs for FA This work in this Renewal could lead to novel therapies for FA

Friedreich‘s共济失调(FA)是一种神经和心脏退行性疾病，线粒体中有有毒铁(Fe)的积聚。我们目前的NHMRC基金的研究表明铁在FA的病理中起着重要的作用事实上，CIS剖析了线粒体铁负载的机制，并在过去两年中在高影响力的期刊上发表了8篇论文，其中3篇发表在美国国家科学院院刊上。对这一过程的理解导致了FA合理化药物的设计。这项更新的工作可能会导致FA的新疗法